RxDoctor Payments Data

Kalpana Cheeti, MD

Geriatric Medicine · Hackensack, NJNPI 1649352857

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations.

$2,336in general payments, 2019–2025

Across 180 payments — averaging $12.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$303
  • Johnson & Johnson$220
  • Amgen$216
  • Lilly USA, LLC$195
  • Merck$191
  • Boehringer Ingelheim$188
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$291%
  • Food & beverage$2,23095%
  • Education$773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,336 in reported general payments places this provider in the 80th percentile of 165 geriatric medicine providers in New Jersey.

See all geriatric medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$100,910
Medicare patients
358
Services billed
1,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate14$14,891
EliquisApixaban21$11,790
XareltoRivaroxaban12$8,721
LivaloPitavastatin Calcium14$6,363
Pitavastatin Calcium14$4,916
Atorvastatin Calcium294$3,108
Rosuvastatin Calcium177$2,791
Amlodipine Besylate240$1,771
Levothyroxine Sodium174$1,575
Escitalopram Oxalate111$1,295
Simvastatin101$1,244
Metformin Hcl104$1,203
Pravastatin Sodium55$1,180
Valsartan44$1,169
Losartan Potassium141$1,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$191$14,89114 claims
PfizerEliquis$185$11,79021 claims
Johnson & JohnsonXarelto$220$8,72112 claims
Kowa Pharmaceuticals America, Inc.Livalo$27$6,36314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 geriatric medicine providers in New Jersey.

Other geriatric medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →